COMPUTATIONAL INSIGHT INTO PIPER RETROFRACTUM CONSTITUENTS TARGETTING MAO-B IN PARKINSON'S DISEASE

Read full text Summarise with VIRAT
Authors: Aisyah Nur, Wahyuni Sri, Aprilliana Kurnia Ulla, Salsabilla Rifa Alya, Fathin Nayla Maymuna, Rusdin Agus, Dhania Novitasari
Cited by: 0
References: 16

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Parkinson’s disease, characterized as a progressive neurodegenerative condition, represents a significant contributor to mortality in Indonesia. Piper retrofractum, a Piperaceae species rich in alkaloids, has been reported to contain compounds with neuroactive potential, similar to other Piper species in which Monoamine Oxidase-B (MAO-B) inhibition has been documented. However, no computational study has evaluated the interaction between Piper retrofractum bioactive compounds and MAO-B. = aimed to evaluate the MAO-B inhibitory potential of bioactive compounds from Piper retrofractum. Ten bioactive compounds from Piper retrofractum were screened and analyzed using Lipinski’s rules, PreADMET, pharmacophore modeling (Ligandscout 4.4.5), and molecular docking (AutoDock 4.2.6). The findings revealed that all test compounds met Lipinski's rule of Five. From the PreADMET results, Alismoxide showed a high Blood-Brain Barrier (BBB) crossing capacity of 4.59529. Trans-fagaramide was identified as the optimal pharmacophore match, displaying a fit score of 34.57. Meanwhile, from the molecular docking results, the most promising pharmacological candidate was piperolein-B, which formed a hydrogen bond with the amino acid residue LEU: A56, similar to the native ligand, with an inhibition constant of 0.015 μM and a binding energy of -10.6 kcal/mol. From these results, the bioactive compounds from Piper retrofractum can interact with the MAO-B receptor. These findings are computational predictions and require further experimental validation to confirm their potential for Parkinson’s disease treatment.

Fields of Study & Subjects

Computational Drug Discovery Methods Piperaceae Chemical and Biological Studies Cholinesterase and Neurodegenerative Diseases

Publication details

Journal / source
Pharmacoscript
Volume
9
Issue
1
Pages
167–183
Publication date
28 February 2026
Language
EN